Lungs News and Research

RSS

Tumor-suppressing protein acts as dimmer switch to dial down gene expression

A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014.

11 Apr 2014

Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

The Clinical Research Forum has announced the winners of its third annual Top 10 Clinical Research Achievement Awards. The winning projects represent the outstanding examples of research projects that benefit the health and well-being of the general public.

11 Apr 2014

Researchers discover mechanism that control normal lung function in patients with BHD syndrome

Researchers at Penn Medicine have discovered that the tumor suppressor gene folliculin (FLCN) is essential to normal lung function in patients with the rare disease Birt-Hogg-Dube (BHD) syndrome, a genetic disorder that affects the lungs, skin and kidneys. Folliculin's absence or mutated state has a cascading effect that leads to deteriorated lung integrity and an impairment of lung function, as reported in their findings in the current issue of Cell Reports.

11 Apr 2014

Study looks at factors that influence life expectancy of childhood cancer survivors

Many factors influence the life expectancy of childhood cancer survivors: not getting enough exercise, being underweight, and being worried about their future health or their health insurance. These are the findings of research led by Cheryl Cox of the St. Jude Children's Research Hospital in the US, published in Springer's Journal of Cancer Survivorship. The study found that, on average, childhood cancer survivors passed away before they were 40 years old.

11 Apr 2014

New edition of RADAR includes review of glycopyrronium for COPD treatment

NPS MedicineWise has published a new edition of RADAR, including a review of glycopyrronium (Seebri Breezhaler), a new medicine for the treatment of chronic obstructive pulmonary disease (COPD).

10 Apr 2014

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test.

10 Apr 2014

Researchers find that cancer gene require copper to promote tumor growth

Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer, researchers at Duke Medicine report.

10 Apr 2014

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis.

10 Apr 2014

CAP receives CDC grants to improve adoption of evidence-based laboratory testing guidelines

The College of American Pathologists (CAP), the world's largest organization of board-certified pathologists, has been awarded two grants from the Centers for Disease Control and Prevention (CDC).

10 Apr 2014

Study identifies two cell surface receptors that may be responsible for spread of lung cancer

Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute.

10 Apr 2014

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.

10 Apr 2014

Treating advanced cervical cancer: an interview with Dr. Krishnansu Tewari

Cervical cancer affects approximately 500,000 women every year globally of which 250,000 die annually, making it the 2nd leading cause of cancer-related death in women.

9 Apr 2014

Study: Honokiol reduces proliferation of renal cell carcinoma

A new study shows that honokiol, a small molecule polyphenol extract derived from Magnolia officinalis bark, reduces proliferation of renal cell carcinoma.

9 Apr 2014

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

9 Apr 2014

Researchers demonstrate advantages of HOPE fixation strategy

They discovered that the so-called HOPE method allows tissue samples to be treated such that they do not only meet the requirements of clinical histology, but can still be characterised later on by modern methods of proteomics, a technique analysing all proteins at once.

9 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Curis, Inc., an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, today announced presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

8 Apr 2014

Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

Fred Hutchinson Cancer Research Center scientists striving for new cancer cures - and the patients who stand to benefit from them - got an enormous boost today when the Bezos family committed $20 million to support the development of novel cancer immunotherapies. It is the largest single contribution in Fred Hutch's history.

8 Apr 2014

USPTO grants patent for low-cost dry powder inhaler to Hovione

Hovione announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This happened less than three years after the patent was filed and after just one Office Action - unusual speed for an inhaler application.

8 Apr 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Lungs News and Research

Tumor-suppressing protein acts as dimmer switch to dial down gene expression

Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

Researchers discover mechanism that control normal lung function in patients with BHD syndrome

Study looks at factors that influence life expectancy of childhood cancer survivors

New edition of RADAR includes review of glycopyrronium for COPD treatment

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

Researchers find that cancer gene require copper to promote tumor growth

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

CAP receives CDC grants to improve adoption of evidence-based laboratory testing guidelines

Study identifies two cell surface receptors that may be responsible for spread of lung cancer

Moffitt Cancer Center initiates phase I clinical trial of cancer vaccine ID-G305

Treating advanced cervical cancer: an interview with Dr. Krishnansu Tewari

Study: Honokiol reduces proliferation of renal cell carcinoma

Researchers identify novel compound effective against drug-resistant lung cancer

Researchers demonstrate advantages of HOPE fixation strategy

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

Curis and Debiopharm present data for Debio 0932 at Annual Meeting of AACR

Bezos family gifts $20M to Fred Hutchinson scientists for development of novel cancer immunotherapies

USPTO grants patent for low-cost dry powder inhaler to Hovione

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News